| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| lexatumumab | tumor necrosis factor receptor superfamily member 10b | biotech | NA | drugbank , DGIDB | Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
54.56 | investigational | unknown |
| lexatumumab | tumor necrosis factor receptor superfamily member 10b | biotech | NA | drugbank , DGIDB | Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
54.56 | investigational | antibody |
| lexatumumab | trail receptor 2 | NA | Clinical trial target | TTD , DGIDB | Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
54.56 | phase 2 | unknown |
| lexatumumab | trail receptor 2 | NA | Clinical trial target | TTD , DGIDB | Neoplasms[MeSHID:D009369] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant Neoplasms[MeSHID:D009369] |
54.56 | phase 2 | antibody |
| click here to return to the previous page | ||||||||